Business
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation,
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":"BEDFORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held April 23 - 27 in New Orleans, Louisiana. “At this year’s Annual Meeting, we are thrilled to be presenting clinical and pre-clinical data from our lead programs as well as from programs that are a part of our early-stage pipeline,” commented Rabia Gurses-Ozden, MD, Chief Medical Officer of Ocular Therapeutix. “The data being presented continues to highlight the depth of our hydrogel platform and its potential to provide solutions that improve efficacy and reduce the complexity and burden of the current standard of care for a number of diseases in both the front and back-of-the-eye. Specifically, we are excited to have Dr. Andrew Moshfeghi presenting an update on OTX-TKI that will cover preclinical pharmacokinetics, the implant bioresorption process and a review of the 10 month interim results from the ongoing U.S. trial. Overall, we are excited about our progress, across our pipeline, and look forward to sharing these updates at ARVO.” Ocular Therapeutix Presentations at ARVO:OTX-TKI (axitinib intravitreal implant) (wet AMD and other retinal diseases): Title: U.S. Phase 1 Study of Intravitreal Axitinib Implant (OTX-TKI) for Neovascular Age-related Macular DegenerationSession Title: AMD: New drugs, delivery systems and mechanisms of action 1Session Date/Times: April 23, 2023 from 6:15 PM to 6:30 PM EDTPresentation type: Paper sessionPresenter: Andrew A. Moshfeghi, M.D. OTX-TIC (travoprost intracameral implant) (primary open-angle glaucoma or ocular hypertension): Title: Preclinical Safety and Tolerability of Repeated Intracameral Travoprost Implant (OTX-TIC) AdministrationsSession Title: Clinical Studies and Clinical ResearchSession Date/Times: April 26, 2023 from 11:30 AM to 1:25 PM EDTPresentation type: Poster sessionPresenter: Chintan Patel, Ph.D. Title: Presence of Medical Conditions that Can Impair Patients with Glaucoma from Administering Topical Glaucoma Medications – A Study using the Sight Outcomes Research Collaborative (SOURCE) RepositorySessio...